VitaSmart™ Receives FDA De Novo Clearance: A New Era in Organ Preservation
Bridge to Life™ Ltd. announced an important milestone with the recent FDA De Novo clearance for their VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System. This groundbreaking development is the first of its kind in the United States, paving the way for significant advancements in liver transplantation preservation.
The innovative VitaSmart™ system allows for hypothermic oxygenated perfusion of donated livers, enhancing preservation techniques and providing transplant centers with an efficient solution for incorporating HOPE protocols in their practices.
A Transformational Achievement
As stated by Don Webber, CEO and President of Bridge to Life™, this FDA clearance is not just a regulatory achievement but a transformative milestone for liver transplantation. The VitaSmart™ system's recognition reflects its safety and effectiveness according to FDA standards, aligning with real-world best practices in transplantation. This innovation is expected to improve organ utilization and contribute to better clinical outcomes, creating valuable economic benefits for transplant programs.
The Importance of DCD in Liver Transplantation
The inclusion of Donation after Circulatory Death (DCD) grafts in the FDA-cleared labeling signifies the growing interest in optimizing preservation strategies for these donor types. DCD grafts play an essential role in contemporary liver transplantation, and with the availability of an FDA-cleared hypothermic oxygenated perfusion system like VitaSmart™, hospitals can enhance the management of these vital organs.
Supporting Real-World Clinical Needs
The FDA's endorsement also emphasizes the device's versatility for both Donation after Brain Death (DBD) and DCD donors. The labeling does not restrict the duration of machine perfusion, allowing healthcare providers to exercise clinical judgment based on each unique case. This flexibility is crucial for achieving better stability during operations and improving post-transplant results.
Clinical Trials and Economic Advantages
Supported by comprehensive data from the Bridge to HOPE pivotal clinical trial, the FDA’s clearance was grounded in solid clinical evidence. This multicenter study assessed the effectiveness of hypothermic oxygenated perfusion and included a diverse range of donor populations. Results demonstrated a statistically significant improvement in early graft function, confirming the safety profile of the VitaSmart™ system.
In addition to clinical improvements, the economic and operational advantages associated with VitaSmart™ are critical for transplant centers grappling with resource limitations. These benefits include:
- Enhanced organ utilization capabilities.
- Minimized resource usage post-surgery.
- Simplified integration into existing workflows.
- Cost-effective solutions for advanced organ preservation.
These factors make VitaSmart™ an attractive option for hospitals to consider as they strive to optimize both clinical and operational outcomes.
Launching the Future of Liver Preservation
Bridge to Life™ is set to launch the VitaSmart™ system commercially in the U.S. during the first quarter of 2026. Under the leadership of David Castiglioni, the newly appointed Chief Commercial Officer, the company aims to leverage its existing infrastructure and partnerships within the transplantation community for a successful rollout.
VitaSmart™ utilizes a specialized hypothermic oxygenated perfusion process that cools donor livers to controlled temperatures while providing oxygen, ensuring organs remain viable leading up to transplantation. Designed for reliability and user-friendliness, this technology empowers a wide range of transplant centers to implement the system effectively under the FDA-cleared indication.
Acknowledgments to Collaborative Teams
Webber expressed gratitude towards the researchers, clinical staff, and transplant teams who contributed to the groundbreaking Bridge to HOPE study. Their commitment and scientific rigor have culminated in this extraordinary achievement, bringing vital improvements to organ preservation.
About Bridge to Life™ Ltd.
Bridge to Life™ Ltd. stands as a global leader in organ preservation technologies. The company offers a robust portfolio of products designed to enhance organ preservation practices, including Belzer UW®, EasiSlush®, and VitaSmart™. With a commitment to advancing the science of preservation and supporting life-saving transplants, Bridge to Life collaborates with organizations worldwide.
Frequently Asked Questions
What is the VitaSmart™ system?
The VitaSmart™ system is a hypothermic oxygenated perfusion technology designed for liver transplantation, recently cleared by the FDA.
How does the clearance impact liver transplantation?
The FDA clearance allows U.S. transplant centers to use the VitaSmart™ system, enhancing liver preservation and improving clinical outcomes.
What are DCD and DBD donors?
DCD refers to Donation after Circulatory Death and DBD to Donation after Brain Death, both important donor categories in liver transplantation.
When will VitaSmart™ be commercially available?
The commercial launch of VitaSmart™ is anticipated in the first quarter of 2026.
Why is the FDA clearance significant?
The FDA clearance is a landmark achievement that establishes a safe and effective pathway for the use of hypothermic oxygenated perfusion in liver transplantation.
